Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NLD
|
|||
| Former ID |
DNCL002413
|
|||
| Drug Name |
ARRY-300
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Array BioPharma; Novartis Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00828165) A Safety Study of ARRY-300 in Healthy Subjects. U.S. National Institutes of Health. | |||
| REF 2 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.